Evidence map›Paper›PMID 42660571›Full record

GuidelineESMO open2026

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma.

C K Tan, A Vogel, Y F Wong, G F Ho, J Zhou, T D Atmakusuma, P Kulkarni, T Kodama, H J Chon, M Bello and 20 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

C K TanCancer Centre, PICASO Hospital, Petaling Jaya, Selangor, Malaysia. Electronic address: tanchihkiang@gmail.com.
A VogelDepartment of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, Hannover Medical School, Hannover, Germany; Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Y F WongDepartment of Radiotherapy & Oncology, National Cancer Institute, Putrajaya, Malaysia.
G F HoM. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Selangor, Malaysia.
J ZhouDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
T D AtmakusumaDepartment of Hematology and Medical Oncology, Internal Medicine Department, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
P KulkarniMedical Oncology, VLM Cancer Center, Deenanath Mangeshkar Hospital and Research Center, Pune, India.
T KodamaDepartment of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine, Suita, Osaka, Japan.
H J ChonDivision of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
M BelloDepartment of Medical Oncology, Saint Luke's Medical Center, Quezon City, Philippines.
W P YongDepartment of Haematology-Oncology, National University Cancer Institute, Singapore.
C HsuDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
K KorphaisarnDivision of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok.
S TanasanvimonDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
S-C ChenDepartment of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
S Y LeeDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
M R SebastianSection of Medical Oncology, Jose Reyes Medical Memorial Medical Center, Manila, Philippines.
S J HuhDivision of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea.
C MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
P TiwariDepartment of Medical Oncology, Artemis Hospital, Gurgaon, Haryana, India.
K F KalistaDivision of Hepatobiliary, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
S QinDepartment of Medical Oncology, GI Cancer Center, Nanjing Tianyinshan Hospital, Nanjing, China.
E C SmythOxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK.
E LimDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
T C HouM. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Selangor, Malaysia.
G PentheroudakisESMO, Lugano, Switzerland.
C W ShanM. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Selangor, Malaysia.
F AndréBreast Cancer Unit, Department of Medical Oncology, Gustave Roussy, Villejuif, France.
T MuthukkumaranDepartment of Radiotherapy and Oncology, Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia.
M DucreuxUniversité Paris-Saclay, INSERM U1279, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma (HCC) were published in May 2025 and were adapted in August 2025, according to previously established standard methodology, to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with HCC. The adapted guidelines presented in this manuscript are the consensus opinions reached by a panel of Asian experts in the treatment of patients with HCC representing the oncological societies of China (Chinese Society of Clinical Oncology), Indonesia (Indonesian Society of Hematology and Medical Oncology), India (Indian Society of Medical and Paediatric Oncology), Japan (Japanese Society of Medical Oncology), Korea (Korean Society of Medical Oncology), Malaysia [Malaysian Oncological Society (MOS)], the Philippines (Philippine Society of Medical Oncology), Singapore (Singapore Society of Oncology), Taiwan (Taiwan Oncology Society), and Thailand (Thai Society of Clinical Oncology) and coordinated by ESMO and the MOS. The voting was based on scientific evidence and was independent of current treatment practices, drug access restrictions, and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with HCC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between the different regions.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMedical OncologyAsiaHumansPractice Guidelines as TopicSocieties, MedicalESMOguidelineshepatocellular carcinomaPan-Asiantreatment

Identifiers

PMID42660571
PMCPMC13542233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.